

Mediclinic International plc  
(Incorporated in England and Wales)  
Company Number: 08338604  
LSE Share Code: MDC  
JSE Share Code: MEI  
NSX Share Code: MEP  
ISIN: GB00B8HX8Z88  
LEI: 2138002S5BSBIZTD5160  
South African income tax number: 9432434182  
(‘Mediclinic’, the ‘Company’, or the ‘Group’)

18 August 2022

TR-1: Standard form for notification of major holdings

## 1. Issuer Details

### ISIN

GB00B8HX8Z88

### Issuer Name

MEDICLINIC INTERNATIONAL PLC

### UK or Non-UK Issuer

UK

## 2. Reason for Notification

An acquisition or disposal of voting rights

## 3. Details of person subject to the notification obligation

### Name

JPMorgan Chase & Co.

### City of registered office (if applicable)

### Country of registered office (if applicable)

US

## 4. Details of the shareholder

Name	City of registered office	Country of registered office
J.P. Morgan Securities plc		

## 5. Date on which the threshold was crossed or reached

16-Aug-2022

## 6. Date on which Issuer notified

18-Aug-2022

## 7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	3.512201	4.885164	8.397365	61909055
Position of previous notification (if applicable)	2.909403	4.879603	7.789006	

## 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

### 8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00B8HX8Z88		25893486		3.512201
Sub Total 8.A	25893486		3.512201%	

### 8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1				

### 8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Cash-settled Equity Swap	02/06/2023	02/06/2023	Cash	143409	0.019452
Cash-settled Equity Swap	12/07/2023	12/07/2023	Cash	10861	0.001473
Cash-settled	06/09/2023	06/09/2023	Cash	13795	0.001871

Equity Swap					
Cash-settled Equity Swap	12/02/2024	12/02/2024	Cash	11913	0.001616
Cash-settled Equity Swap	09/07/2029	09/07/2029	Cash	65281	0.008855
Cash-settled Equity Swap	03/08/2027	03/08/2027	Cash	289	0.000039
Cash-settled Equity Swap	06/07/2027	06/07/2027	Cash	309	0.000042
Cash-settled Equity Swap	23/11/2022	23/11/2022	Cash	28558635	3.873703
Cash-settled Equity Swap	09/08/2023	09/08/2023	Cash	759	0.000103
Cash-settled Equity Swap	22/08/2023	22/08/2023	Cash	598	0.000081
Cash-settled Equity Swap	01/02/2023	01/02/2023	Cash	16152	0.002191
Cash-settled Equity Swap	22/02/2023	22/02/2023	Cash	117	0.000016
Cash-settled	04/07/2023	04/07/2023	Cash	7193451	0.975722

Equity Swap					
Sub Total 8.B2				36015569	4.885164%

## 9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
JPMorgan Chase & Co.	J.P. Morgan Securities plc		4.885164	7.119446%
JPMorgan Chase & Co.	JPMorgan Chase Bank, National Association			
JPMorgan Chase & Co.	J.P. Morgan Equities South Africa Proprietary Limited			
JPMorgan Chase & Co.	J.P. Morgan Securities LLC			

## 10. In case of proxy voting

**Name of the proxy holder**

**The number and % of voting rights held**

**The date until which the voting rights will be held**

## 11. Additional Information

Chain of controlled undertakings:

JPMorgan Chase & Co.

JPMorgan Chase Bank, National Association (100%)

J.P. Morgan International Finance Limited (100%)

J.P. Morgan Capital Holdings Limited (100%)  
J.P. Morgan Securities plc (100%)

JPMorgan Chase & Co.  
JPMorgan Chase Bank, National Association (100%)

JPMorgan Chase & Co.  
JPMorgan Chase Bank, National Association (100%)  
J.P. Morgan International Finance Limited (100%)  
J.P. Morgan Capital Holdings Limited (100%)  
J.P. Morgan Equities South Africa Proprietary Limited (100%)

JPMorgan Chase & Co.  
JPMorgan Chase Holdings LLC (100%)  
J.P. Morgan Broker-Dealer Holdings Inc. (100%)  
J.P. Morgan Securities LLC (100%)

## 12. Date of Completion

18-Aug-2022

## 13. Place Of Completion

London

### About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 30 June 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 20 day case clinics and 23 outpatient clinics. The Swiss operations included 17 hospitals and four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

**Company Secretary, Link Company Matters Limited**

Caroline Emmet  
+44 (0)333 300 1930

**Investor Relations**

James Arnold, Head of Investor Relations  
[ir@mediclinic.com](mailto:ir@mediclinic.com)  
+44 (0)20 3786 8181

**Media queries**

FTI Consulting  
Ben Atwell/Ciara Martin – United Kingdom  
+44 (0)20 3727 1000  
Sherryn Schooling – South Africa  
+27 (0)21 487 9000

**Registered address:** 6<sup>th</sup> Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

**Website:** [www.mediclinic.com](http://www.mediclinic.com)

**Corporate broker (United Kingdom):** Morgan Stanley & Co International plc and UBS Investment Bank

**JSE sponsor (South Africa):** Rand Merchant Bank (A division of FirstRand Bank Limited)

**NSX sponsor (Namibia):** Simonis Storm Securities (Pty) Ltd